---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-005242"
form_type: "8-K"
ticker: "FNCHQ"
cik: "0001733257"
company_name: "Finch Therapeutics Group, Inc."
filed_at: "2022-03-31T23:59:59+00:00"
generated_at: "2026-06-26T12:19:15.521664+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Finch Therapeutics Q4 2021 net loss $19.1M; PRISM4 trial on hold, CFO retiring

## Summary
- Net loss of $19.1M in Q4 2021 ($13.1M in Q4 2020); full year loss $58.2M ($39.3M in 2020).
- Cash and equivalents $133.5M at Dec 31, 2021; expected to fund operations into mid-2023.
- PRISM4 Phase 3 trial of CP101 in recurrent C. difficile remains on clinical hold; at least one quarter delay.
- Paused development of CP101 for chronic HBV to focus on CDI and autism programs.
- CFO Greg Perry to retire April 30, 2022; COO Marc Blaustein to serve as principal financial officer.

## SEC filing metadata
- accession: 0000950170-22-005242
- form_type: 8-K
- ticker: FNCHQ
- cik: 0001733257
- company_name: Finch Therapeutics Group, Inc.
- filed_at: 2022-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733257/000095017022005242/0000950170-22-005242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733257/000095017022005242/fnch-20220331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-005242
- JSON: https://secwatch.observer/filing/0000950170-22-005242.json
- Plain text: https://secwatch.observer/filing/0000950170-22-005242.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.